China’s one-stop organoid technology and solutions provider bioGenous expects to build a global leading organoid modeling platform
bioGenous (Chinese：伯桢生物) announced the completion of a CNY 100 million Series A round of financing, with the participation led by SDIC (Chinese: 国投招商) and followed by its existing investor Marathon Venture Partners (Chinese: 远毅资本).
Proceeds will be mainly used to help bioGenous further improve the global leading organoid CDMO and CRO technology system, accelerate the construction and operation of commercialized production base, and expand overseas markets. After this proceeding, bioGenous will continuously strengthen the multi-cancer organoid culture, gene manipulation, drug development and drug efficacy evaluation, platform capabilities including experimental animal transplantation, and comprehensively increase production capacity.
bioGenous is a company focusing on the base technology innovation in organoid industry and dedicated to providing standardized and modular organoid product and technology for biomedical sciences research, drug research and development and accurate clinical medicine. It has 3000 square meters R&D base and 3 research and operation centers in Suzhou, Shanghai, and Texas. In 2023, bioGenous will have 4 reagents and test kits production lines that meet B-GMP standard, 6 organoid technology and service production lines that meet C-GMP standard, and more than 10 cleanrooms. Now company has conducted in-depth cooperations with more than 300 Three-A hospitals, drug development companies, and scientific institutes.
The company's competitors include K2 Oncology (Chinese: 科途医学), Accurate International (Chinese：创芯国际), and Daxiang Biotech (Chinese: 大橡科技).